AZAlexander E. Zhigulin

Alexander E. Zhigulin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander E. Zhigulin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic Yield and Variant Spectrum in 375 Patients with Segmental Overgrowth and Vascular Malformations: Implications for Panel Design and Molecular Testing Strategies

    by Ekaterina V. Bychkova, Natalia A. Semenova, Garik B. Sagoyan, Seyfulla V. Alimov, Alexander E. Zhigulin, Grigory A. Somsikov, Ruslan A. Khagurov, Daria M. Guseva, Ilya V. Volodin, Sergey I. Kutsev, et al.

    Segmental overgrowth and vascular malformations comprise a group of diseases caused by postzygotic variants in genes that regulate cell growth, proliferation, and angiogenesis. The best-characterized group is the PIK3CA-related overgrowth spectrum (PROS), which includes syndromes sharing variants in the PIK3CA gene. Beyond PIK3CA, the genes involved fall into two mechanistically distinct groups, with gain-of-function (GNAQ, GNA11, TEK, AKT1, AKT3, MTOR, PIK3R1) and loss-of-function (RASA1, GLMN, PTEN) causative variants. What remains poorly established is how effectively a molecular diagnosis is actually achieved in routine practice, and how this depends on the referral clinical diagnosis. By targeted panel deep sequencing in patients with segmental overgrowth and/or a vascular malformation, we have identified at least one pathogenic / likely pathogenic (P/LP) genetic variant in 266 of the 375 successfully tested patients, giving an overall diagnostic yield of 70.9%. The yield was 63.5% in patients with isolated overgrowth (94 of 148), 75.0% in patients with an isolated vascular malformation (111 of 148) and 77.2% in patients with a combined or syndromic phenotype (61 of 79). The 277 P/LP variants identified were distributed across 17 genes; PIK3CA accounted for 141 variants (50.9%), GNAQ for 44 (15.9%), TEK for 31 (11.2%), RASA1 for 15 (5.4%) and GNA11 for 11 (4.0%); these five genes together accounted for 87.4% of the variants. The spectrum was highly concentrated: the ten most frequent variants accounted for 57.0% of the P/LP variants, with GNAQ variant p.Arg183Gln (15.2%) and PIK3CA hotspot variants p.Glu542Lys (8.7%), p.Glu545Lys (6.9%), and p.His1047Arg (7.6%). In several genes, variants were restricted to specific regions: in GNAQ and GNA11 to two codons, 183 and 209 (98.2% of all findings), and in TEK to the 3′-terminus. Considered together with the referral diagnosis, the distribution of variants, their allele fractions and their mechanisms of pathogenicity suggest molecular testing strategies.